Among patients with chronic kidney disease (CKD) in the United States, HCV infection causes significant morbidity and mortality and results in substantial healthcare costs. A once-daily oral regimen of elbasvir/grazoprevir (EBR/GZR) for 12 weeks was found to be a safe and efficacious treatment for HCV in patients with CKD. We evaluated the cost-effectiveness of EBR/GZR in treatment-naïve and treatment-experienced CKD pa- 
| INTRODUCTION
The burden of chronic kidney disease (CKD) in terms of increased risk for cardiovascular disease, hospitalizations and mortality is significant. More than 20 million persons are believed to have CKD at varying stages of progression in the United States (US) and approximately 113 000 patients started treatment for end-stage renal disease (ESRD) in 2011.
1-3 HCV infection is prevalent among CKD patients, with an overall prevalence among haemodialysis patients in the United States of 9.9%. 4 Hepatitis C virus (HCV) infection has been associated with significant morbidity including liver disease-related deaths, and cardiovascular mortality among patients with CKD. [5] [6] [7] [8] The prevalence of HCV in the CKD population is much higher than that of the general population.
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Treatment options for patients with HCV and CKD (especially stages 4-5) are limited. Most of the currently available all-oral regimens (i) were not evaluated in randomized controlled trials in patients with abnormal kidney function, (ii) are not optimal for patients with patients because they include ribavirin, which is associated with anaemia, or (iii) they contain drugs whose metabolites are cleared by the kidney (such as sofosbuvir). 10 Elbasvir (EBR, NS5A inhibitor)/grazoprevir (GZR, NS3/4A protease inhibitor) were recently studied in the C-SURFER (Hepatitis C: Study to Understand Renal Failure's Effect on Responses) study, a phase 2/3 double-blind, placebo-control trial in HCV genotype 1 patients with CKD4/5. 11 The study demonstrated that a once-daily oral regimen of EBR/GZR for 12 weeks was safe and can achieve high rates of SVR across many CKD patient subgroups, including those receiving haemodialysis.
The decision to treat HCV in patients with CKD requires weighing the potential health benefits, risks and costs of therapy. 12 The objective of this study was to assess the cost-effectiveness of EBR/GZR in patients with CKD compared with no treatment (NoTX) and pegylated interferon plus ribavirin (peg-IFN/RBV).
| METHODS
To represent the natural history of chronic HCV genotype 1 infection, CKD and liver disease, a computer-based, discrete-time, statetransition semi-Markov model was developed and programmed in Microsoft Excel (Microsoft Corp., Redmond, WA). The model is fully parameterized to run the base case and sensitivity analysis. One-way deterministic sensitivity analysis (DSA) and probabilistic sensitivity analysis (PSA) were implemented using Visual Basic macros. The model combines major complications of both CKD and liver disease.
The health states for CKD are defined according to the National Kidney Foundation K/DOQI guidelines which are based on kidney damage or glomerular filtration rate (GFR).
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Because CKD increases the risk of cardiovascular complications, we explicitly modelled the incidence of myocardial infarction (MI) and stroke. Baseline probabilities of MI and stroke are derived from the age-and sex-based Framingham risk equations. 13 Model risk factors include diabetes status, systolic blood pressure (SBP), left ventricular hypertrophy (LVH), total and high-density lipoprotein cholesterol levels and smoking status.
Baseline probabilities of MI and stroke obtained from the Framingham risk equations were adjusted by CKD stage-specific hazard rates. To take into account the increased risk of developing ESRD or death from HCV infection among patients with CKD, we adjusted the baseline CKD progression probabilities and other-cause mortality using hazard rates obtained by comparing progression and mortality rates among HCV-infected patients with rates among patients without HCV.
The structure of the HCV and liver complications model was based on our previously published and validated Markov cohort model.
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The HCV model is a multicohort Markov model that simulated each cohort using the natural history of progression of HCV disease. The CKD model builds on the framework of previous models [17] [18] [19] [20] [21] [22] ( Figure 1 ). The health states for CKD are defined following the National Kidney Foundation K/DOQI guidelines. 7 CKD stages are as follows:
CKD1 (GFR ≥90 mL/min), CKD2 (GFR 60-89 mL/min), CKD3a (GFR 45-59 mL/min), CKD3b (GFR 30-44 mL/min), CKD4 4 (GFR 15-29 mL/min) and CKD 5 (GFR<15 mL/min). 23 In addition, we also include separate health states for haemodialysis (HD) and kidney transplantation (KT).
The combined models consists of 80 mutually exclusive states representing CKD status (CKD1, CKD2, CKD3a, CKD3b, CKD4, CKD5, HD and KT) and liver disease conditions (SVR-F0-F3; SVR-F4, F0,   F1, F2, F3, in CKD patients may progress to (i) more severe HCV disease only; (ii) CKD disease only; or (iii) both. For example, a patient with CKD3a and fibrosis level F0 (CKD3a-F0) can progress to CKD3b-F0, CKD3a-F1, CKD3b-F1, can suffer an MI or stroke, can die from all causes or MI or stroke, or remain in CKD3a-F0.
| Treatmentcomparators
The clinical and economic impact of using EBR/GZR was compared against that of no treatment (NoTx), and pegylated interferon (peg-IFN) with ribavirin (RBV) (peg-IFN/RBV) in CKD patients with chronic HCV GT1 infection.
| Modelinputs
CKD model inputs were derived from a targeted review of the published literature (Table 1) . HCV model parameters were obtained from our previous studies 12 (Table 1) .
| Efficacy
Efficacy of EBR/GZR was obtained from C-SURFER (a randomized, parallel-group, multisite, placebo-controlled trial). In the prespecified 
| Mortality
Background, other-cause mortality rates for patients in each CKD stage were assumed to be the same as the age-and sex-specific mortality in the general population obtained from U.S. life tables.
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Because of high CVD-attributable mortality among patients with CKD, we subtracted the expected CVD mortality rates 28 from the baseline all-cause mortality rates to avoid double counting. Excess diseaserelated mortality rates as a result of CKD, CVD or liver disease were derived from published literature ( Table 1) .
| Cardiovasculardisease
Patients can have a stroke event or an MI event. 
| Costs
Costs (inpatient, outpatient and pharmaceutical) of managing CKD by stage are based on a cost function developed by Smith et al.
29
that used data from members of the Kaiser Permanente Northwest (Portland, Oregon).
| Utilities
Utilities for each disease and stage were derived from the published literature (Table 1) . Several methods can be used to describe the utilities for HCV and CKD disease combination: 30 minimum, geometric mean, simple average, weighted average and maximum of the utilities of the two diseases. We combined utilities using the simple average of the two utilities and tested the sensitivity of the results using alternative methods.
| Modeloutcomes
We calculated lifetime risk of liver disease complications, life expectancy, discounted treatment costs, discounted health state costs and discounted QALYs. We applied within-cycle correction to all cumulative outcomes using Simpson's 1/3rd rule and tested sensitivity of the results to the method of correction by applying the standard application of half-cycle correction method. 31 For the cost-effectiveness analysis, we calculated costs and QALYs over the remaining duration of a patient's lifetime. Cost-effectiveness of an EBR/GZR regimen relative to a comparator was evaluated using the incremental costutility ratio (ICUR) obtained by dividing incremental total discounted costs by the incremental total discounted number of QALYs resulting from using EBR/GZR regimen instead of the comparator. We also calculated the incremental cost-effectiveness ratios (ICER) as the ratio of incremental total discounted costs and incremental total discounted number of life year (LY) resulting from using two different regimens.
| Modelpredictionsandvalidation
The face validity of the model was checked during collaboration with experts from the relevant fields of medicine, in consultation with health economists and decision scientists, and by comparing its structure with that of previously published models. 12, 15, 16, 16, 17, [17] [18] [19] Several tests were built into the model for verification and to ensure internal validity. For example, the sum of the distribution of persons in each health state at the end of each cycle was verified to be equal to 1 both numerically using Microsoft Excel (Microsoft Corp., Redmond, WA) and analytically by transferring the formula into Mathematica (Wolfram Research, Inc., Champaign, IL, USA) and using the built-in algebraic functions within Mathematica to manipulate the resulting expressions.
| MODELANALYSIS
The model was run for each of the specified patient profiles. Depending on the type of analysis, an overall weighted average of the results was generated based on the distribution of the patient characteristics at the time of treatment assumed for a given analysis. T A B L E 1 (continued)
| Basecaseanalysis
Aggregated results are presented for the average cohort irrespective of baseline fibrosis/cirrhosis or CKD status.
| Subgroupanalysis
The results are also provided separately by each fibrosis stage for a typical CKD cohort of patients (eg, average age 55 years, 60% men).
The robustness of the results was also tested by changing the baseline demographic characteristics such as sex (ie, proportion of men) and average age.
| Deterministicsensitivityanalysis
We conducted one-way sensitivity analyses for several parameters showing the effect of varying these inputs on the ICUR of EBR/GZR treatment strategies compared with NoTx or peg-IFN/ RBV. We varied progression rates, efficacy, unit costs, utility weights, discount rates using the ranges defined in the input tables (Table 1) .
| Probabilisticsensitivityanalysis
To quantify the impact of uncertainty in the estimated parameter values (ie, transition probabilities, SVR, costs and utility weights) on the ICUR of EBR/GZR treatment strategies compared with NoTx or peg-IFN/RBV, we performed probabilistic sensitivity analysis (PSA). Using
Monte Carlo simulations methods, we drew 1000 random samples from predefined distributions ( Table 1 ).
The parameters of the Gamma and Beta distributions were estimated using the method of moments that relates each parameter to the mean and standard deviation. We used the base case values as estimates of the mean. Standard errors were estimated from confidence intervals or ranges (Supplementary Information).
Results of the PSA were summarized using descriptive statistics and presented using cost-effectiveness acceptability curves (CEAC). 32 The CEAC summarizes uncertainty in the results of the cost-effectiveness analysis by showing the probability a regimen is cost-effective as a function of willing-to-pay for a QALY gained.
| RESULTS

| Basecaseresults
Our model predicted that EBR/GZR would significantly reduce the incidence of liver-related complications and prolong life in patients with chronic HCV G1 infection and CKD compared with no treatment or use of peg-IFN/RBV. Compared with NoTx, use of EBR/GZR was projected to reduce the lifetime cumulative incidence of HCC from 23.19% to 0.92% (Table 2 ). EBR/GZR-based regimens reduced life- 
| Subgroupanalysis
The ICUR and ICER of EBR/GZR compared with NoTx were consistently low across baseline fibrosis or cirrhosis status and are lower the more severe the status (Figure 2) . Because of the impact of HCV and CKD on quality of life, the ICUR (whose denominator is QALYs)
of EBR/GZR compared with NoTx was consistently lower than the W. Dominated, weakly dominated (eliminated through extended dominance because it has an ICER that is greater than that of the more effective regimen of EBR/GZR); ICER, incremental cost-effectiveness ratio; ICUR, incremental cost-utility ratio; LYs, life years; QALY, quality-adjusted life years. 
| Deterministicsensitivityanalysis
By varying the values of inputs one at a time, we identified the 10 most influential inputs (Figure 3) . The ICUR was most sensitive to changes in discount rates, impact of HCV on CKD progression or death, death from HCC and utility following SVR.
| Probabilisticsensitivityanalysis
The results of 1000 Monte Carlo simulations showed that the mean ESLD mortality with the EBR/GZR-based regimen was 0.23% (95% 
| DISCUSSION
Treatment of patients with hepatitis C infection and chronic kidney disease (CKD) (especially stages 4-5) with EBR/GZR is safe and highly efficacious. However, the decision to treat HCV in patients with chronic The results of the subgroup analysis showed that the costeffectiveness of treatment of patients was more favourable for patients with more severe fibrosis/cirrhosis or less severe CKD disease (Table S1 ). For example, the lowest and the highest ICUR of EBR/GZR compared with NoTx of $9900 and $217 000/QALY was for the treatment of patients at CKD1 and haemodialysis, respectively. At this high ICUR, treatment of patients on haemodialysis may not be considered cost-effective. However, the overall ICUR of using EBR/GZR to treat an average CKD patient chronically infected with HCV compared with NoTx was well below the accepted threshold for cost-effectiveness.
This study made several simplifying assumptions. First, it excluded the risk of HCC even among patients with advanced fibrosis F3. This has the potential of biasing the results against treatment. Second, the model did not stratify the CKD3, CKD4 and CKD5 states according to albuminuria or proteinuria as was performed in some other models. 16, 18 Despite these limitations, our conclusion regarding the costeffectiveness of EBR/GZR-based regimens in patients with CKD is robust to variation in many model inputs.
Several other modelling studies of cost-effectiveness of treating chronic hepatitis C patients in the United States have shown that treatment with all-oral direct-acting antivirals is a good use of limited healthcare resources. 34 Although we studied HCV treatment of patients with CKD, a difficult-to-treat population, our results are broadly consistent with those of studies of general HCV patients.
What is unique about this study is that it combined two disease processes (liver and kidney) into one model, something that is very challenging to analyse mathematically. The information provided by this study can be used by payers to guide optimal allocation of limited resources.
In conclusion, our study suggests that use of EBR/GZR has the potential to substantially reduce the incidence of liver-and CKD- 
